{"title": "Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections", "doi": "10.1101/2020.03.15.993097", "citation_id": "2020.03.15.993097v1", "date": "2020-03-17", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.03.15.993097", "abstract": "<p>The World Health Organization has recently declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, as pandemic. There is currently a lack of knowledge in the antibody response elicited from SARS-CoV-2 infection. One major immunological question is concerning the antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by using plasma from patients infected by SARS-CoV-2 or SARS-CoV, and plasma obtained from infected or immunized mice. Our results show that while cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses is rare, indicating the presence of non-neutralizing antibody response to conserved epitopes in the spike. Whether these non-neutralizing antibody responses will lead to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding the antigenicity differences between SARS-CoV-2 and SARS-CoV, but also has important implications in vaccine development.</p>", "twitter_description": "The World Health Organization has recently declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, as pandemic. There is currently a lack of knowledge in the antibody response elicited from SARS-CoV-2 infection. One major immunological question is concerning the antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by using plasma from patients infected by SARS-CoV-2 or SARS-CoV, and plasma obtained from infected or immunized mice. Our results show that while cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses is rare, indicating the presence of non-neutralizing antibody response to conserved epitopes in the spike. Whether these non-neutralizing antibody responses will lead to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding the antigenicity differences between SARS-CoV-2 and SARS-CoV, but also has important implications in vaccine development.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.15.993097v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.03.15.993097v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.15.993097v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/03/17/2020.03.15.993097.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.03.15.993097v1", "access_rights": "restricted", "authors": ["Huibin Lv", "Nicholas C. Wu", "Owen Tak-Yin Tsang", "Meng Yuan", "Ranawaka A. P. M. Perera", "Wai Shing Leung", "Ray T. Y. So", "Jacky Man Chun Chan", "Garrick K. Yip", "Thomas Shiu Hong Chik", "Yiquan Wang", "Chris Yau Chung Choi", "Yihan Lin", "Wilson W. Ng", "Jincun Zhao", "Leo L. M. Poon", "J. S. Malik Peiris", "Ian A. Wilson", "Chris K. P. Mok"]}